The Landscape of Targeted Therapies in TNBC
A review article that provides an extensive introduction to the changing landscape of treatment for patients with TNBC. In addition to a summary of the molecular profile of TNBC, the article describes the growth of treatment strategies based on the expression of molecular biomarkers and outlines several targeted pathways and emerging therapies. Published in Cancers.
Update on Triple-Negative Breast Cancer Disparities for the United States: A Population-Based Study From the United States Cancer Statistics Database, 2010 Through 2014
Triple negative breast cancer is an aggressive type of breast cancer that disproportionately affects younger women (<40 years) and women of color. This broad geographic descriptive analysis of the US Cancer Statistics database affirms that there is significant burden of TNBC disease in these patient populations, especially non-Hispanc black women and younger women. Racial disparities persist even after accounting for indivdiual level risk factors. It remains important to examine physical, sociual, and environmental characteristics that increase risk and contribute to disparities in TNBC. Published in Cancer.
Triple Negative Breast Cancer Molecular Subtyping and Treatment Progress
This paper provides an overview of TNBC subtypes and assignment of cell lines to subtypes as a foundation for understanding the rationale of current treatment regimens. Published in Breast Cancer Research.
NCCN Guidelines for Patients: Breast Cancer - Invasive
The NCCN guidelines on invasive breast cancer for patients provide an overview of testing, staging, and treatment options. These guidelines were written in 2020 and include only chemotherapy as systemic therapy; however, the guidelines are a helpful resource to which APPs can direct patients for information about questions to ask and words for patients to know.
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Trop-2 expression was medium to high in a majority of patients with mTNBC in the ASCENT trial. This subgroup biomarker analysis evauated the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes. Survival outcomes and overall response rates were numerically higher in patients treated with sacituzumab govitican versus physician's choice treated patients with high/medium Trop-2 expression. Published in Annals of Oncology.